A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata. (NCT07029828)
A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this clinical trial is to learn about long-term safety and long-term effects of the study medicine (called ritlecitinib) for the potential treatment of severe alopecia areata, a condition that causes hair loss. This study is seeking participants who have: * previously completed one of Pfizer's pediatric studies for Alopecia Areata (B7981027 or B7981031). * at least 50% scalp hair loss due to alopecia areata (for participants enrolling from the study B7981031). * received varicella vaccination (2 doses) or have been infected by varicella zoster virus before based on blood test reports. All participants in this study will receive the study medicine (ritlecitinib). Participants who received ritlecitinib higher or lower doses in the parent Study B7981027 will continue receiving the same ritlecitinib dose in this trial. Participants who received placebo in the parent Study B7981027 and all participants from parent Study B7981031 will receive either higher or lower dose of ritlecitinib in this trial. The study medicine is a capsule that is taken by mouth. It is taken 1 time each day at home. The study will help see if ritlecitinib is safe and effective. Participants will take part in this study for a duration of up to 3 years (36 months). During this time, they will have 17 study visits at the study clinic. The study team will also call participants once a month over the phone.
Who can join: Review the eligibility criteria below.
Location: California Dermatology & Clinical Research Institute — Encinitas, California
Age range: 6 Years to 14 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (41 Sites)
Showing the first 25 of 41 sites.
- California Dermatology & Clinical Research Institute — Encinitas, California
- Pediatric Skin Research — Miami, Florida
- D&H Tamarac Research Center — Tamarac, Florida
- Dawes Fretzin Clinical Research Group, LLC — Indianapolis, Indiana
- Kindred Hair and Skin Center — Marriottsville, Maryland
- Michigan Dermatology Institute — Waterford, Michigan
- Ear, Nose & Throat Consultants, LLC — Omaha, Nebraska
- Skin Specialists, PC dba Schlessinger MD — Omaha, Nebraska
- Complete Behavior Health (Dr. Brittany Marshall, Licensed Psychologist) — Papillion, Nebraska
- University of New Mexico Health Sciences Center — Albuquerque, New Mexico
- University of New Mexico-IDS Pharmacy — Albuquerque, New Mexico
- Regents of the University of New Mexico — Albuquerque, New Mexico
- Equity Medical, LLC — The Bronx, New York
- Northwest Dermatology Institute — Portland, Oregon
- Penn State Health Milton S. Hershey Medical Center — Hershey, Pennsylvania
- Medical University of South Carolina Department of Dermatology and Dermatologic Surgery — Charleston, South Carolina
- 3A Research — El Paso, Texas
- Texas Dermatology and Laser Specialists — San Antonio, Texas
- Huashan Hospital, Fudan University — Shanghai, Shanghai Municipality
- Prof. MUDr. Petr Arenberger, DrSc., MBA — Prague,
- Hospices Civils de Lyon - Hopital Femme Mere Enfant — Bron,
- CHU de Dijon Bourgogne — Dijon,
- GHICL - Service d'investigation - Recherche clinique — Lille,
- Hôpital Saint Vincent de Paul — Lille,
- Centre Hospitalier Universitaire de Nice — Nice,
📞 Contact the Study Coordinator
Phone: (800) 718-1021
Email: ClinicalTrials.gov_Inquiries@pfizer.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Severe Alopecia Areata
Explore by condition: All Severe Alopecia Areata clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.